Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

TT-012 has anti-tumor activity, selectively binds dynamic MITF and disrupts the dimer formation and DNA binding of the latter.

Moiramide B is a potent acetyl coenzyme A carboxylase (ACC) inhibitor (IC50:6 nM) with antimicrobial activity, strongly inhibiting Gram-positive bacteria but weakly inhibiting Gram-negative bacteria.